Podcasts
Listen to the latest hemonc news from international experts
The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Beyond BTK inhibition: overcoming resistance and exploring new treatment strategies in CLL
This VJHemOnc podcast explores emerging strategies to overcome treatment resistance in chronic lymphocytic leukemia (CLL), focusing on BTK degraders, novel combination approaches and cellular immunotherapies.
Kerry Rogers, MD, The Ohio State University, Columbus, OH, discusses the mechanism of action of BTK degraders and their potential to overcome resistance to conventional BTK inhibitors, while Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, explores BTK resistance mutations and the potential of BTK degraders in earlier treatment lines and combination regimens. Stephan Stilgenbauer, MD, University of Ulm, Ulm, Germany, reviews findings from the Phase I CaDAnCe-101 trial (NCT05006716) evaluating tacabrutideg in relapsed or refractory CLL, and its potential in earlier lines of treatment. Finally, Prof. Danilov and Marco Ruella, MD, University of Pennsylvania, Philadelphia, PA, discuss the evolving role of CAR T-cell therapy and bispecific antibodies in CLL, including treatment accessibility and patient selection.
Date: 6th November 2026
